Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078258 | 0.93 | HTR1A (0.46) | ALDH1A1TSHRKDM4ENPC1HTR1A | |
| SCHEMBL20444070 | 0.92 | CA2 (0.47) | ALDH1A1USP2LMNATSHRKDM4E | |
| SCHEMBL18782931 | 0.90 | CA2 (0.44) | ALDH1A1USP2LMNATSHRKDM4E | |
| SCHEMBL22628668 | 0.90 | CA2 (0.44) | ALDH1A1USP2LMNATSHRKDM4E | |
| SCHEMBL18949009 | 0.90 | CA2 (0.44) | ALDH1A1USP2LMNATSHRKDM4E | |
| SCHEMBL23691156 | 0.90 | ALDH1A1 (0.56) | ALDH1A1USP2LMNATSHRKDM4E | |
| SCHEMBL21846071 | 0.86 | L3MBTL1 (0.47) | ALDH1A1USP2LMNATSHRCA2 | |
| SCHEMBL20416320 | 0.86 | CYP2C19 (0.47) | ALDH1A1USP2LMNATSHRKDM4E | |
| SCHEMBL23241202 | 0.84 | L3MBTL1 (0.49) | ALDH1A1USP2LMNATSHRCA2 | |
| SCHEMBL23567362 | 0.83 | ALDH1A1 (0.50) | ALDH1A1USP2LMNATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | ALDH1A1 289/4885USP2 1271/4885LMNA 3518/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | ALDH1A1 289/4885USP2 1271/4885LMNA 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.